Lynn Huynh
Manager
Boston
Education
Dr.PH., epidemiology, Johns Hopkins Bloomberg School of Public Health; M.B.A., health economics, Johns Hopkins Carey Business School; M.P.H., concentration in epidemiology and biostatistics, Johns Hopkins Bloomberg School of Public Health; B.A., chemistry, Harvard University
Summary of Experience
Dr. Huynh specializes in epidemiologic methodologies and health economics and outcomes research. She has conducted cost-effectiveness and comparative effectiveness research on various diseases, including neuroendocrine tumors, multiple sclerosis, severe aplastic anemia, metachromatic leukodystrophy, myelofibrosis, epilepsy, hemophilia, thromboembolism, hepatitis B, HIV, primary open angle glaucoma, and dysfunctional uterine bleeding. Dr. Huynh has experience designing and developing case report forms, coordinating with clinical centers for data collection, developing discrete choice experiment surveys, designing quality of life and humanistic burden surveys, conducting qualitative interviews, and performing mixed methods research, systematic reviews, clinical trials design, epidemiological analysis of longitudinal cohort studies, development of discrete event simulation models, and economic evaluation.
Selected Publishing
-
Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group
The Oncologist, 2020
2020Savard MF, Wells JC, Graham J, Dudani S, Steinharter JA, McGregor BA, Donskov F, Bjarnason GA, Vaishampayan UN, Hansen AR, Iafolla MAJ, Zanotti G, Huynh L, Chang R, Duh MS, Heng DYC
-
Burden of illness among patients with severe aplastic anemia who have had insufficient response to immunosuppressive therapy: a multicenter retrospective chart review study
Annals of Hematology, 2020
2020Peffault de Latour R, Huynh L, Ivanova JI, Totev T, Bilginsoy M, Antin J, Roy A, Duh MS
-
Antiproliferative Effects of Telotristat Ethyl in Patients with Neuroendocrine Tumors: The TELEACE Real-World Chart Review Study
Cancer Management and Research, 2020
2020Morse MA, Liu E, Joish VN, Huynh L, Cheng M, Duh MS, Seth K, Lapuerta P, Metz DC
-
Real-World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A Multicenter Retrospective Chart Review Study
The Oncologist, January 3, 2019
2019Kulke MH, Benson AB, Dasari A, Huynh L, Cai B, Totev T, Roesner N, Duh MS, Neary MP, Maurer VE, Shih BE, Dagohoy CG, Chan J, Bergsland EK
-
Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study
The Oncologist, January 4, 2019
2019Dasari A, Bergsland EK, Benson AB, Cai B, Huynh L, Totev T, Shea J, Duh MS, Neary MP, Dagohoy CG, Shih BE, Maurer VE, Chan J, Kulke MH
-
Clinical Outcomes of First-line Sunitinib Followed by Immuno-oncology Checkpoint Inhibitors in Patients With Metastatic Renal Cell Carcinoma
Clinical Genitourinary Cancer, 2019
2019Wells JC, Graham J, Beuselinck B, Bjarnason GA, Donskov F, Hansen AR, McKay RR, Vaishampayan U, De Velasco G, Duh MS, Huynh L, Nguyen C, Zanotti G, Ramaswamy K, Choueiri TK, Heng DYC
-
Value of transfusion independence in severe aplastic anemia from patients’ perspectives – a discrete choice experiment
Journal of Patient-Reported Outcomes. March 01 2018;2(1):13
2018Pickard AS, Huynh L, Ivanova JI, Totev T, Graham S, Mühlbacher AC, Roy A, Duh MS
-
Efficacy of antiepileptic drugs in the adjunctive treatment of refractory partial-onset seizures: Meta-analysis of pivotal trials
Epilepsy Research. 2018 Jul;143:120-129
2018Slater J, Chung S, Huynh L, Duh MS, Gorin B, McMicken C, Ziemann A, Isojarvi J
-
Impact of carcinoid syndrome symptoms and long-term use of somatostatin analogs on quality of life in patients with carcinoid syndrome: A survey study
Medicine. 2018 Nov;97(47):e13390
2018Halperin DM, Huynh L, Beaumont JL, Cai B, Totev T, Bhak RH, Duh MS, Neary MP, Cella D
-
Real-world treatment patterns in advanced pancreatic neuroendocrine tumors in the era of targeted therapy: perspectives from an academic tertiary center and community oncology practices
Medical Oncology. May 2017;34(5):88
2017Herring M, Huynh L, Duh MS, Vekeman F, Tiew A, Neary M, Bergsland E
-
Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR
Journal of Medical Economics. Jun 19 2017:1-7
2017 -
Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with a(1)
Journal of Medical Economics. 02 Sep 2017;20(9):945-951
2017